Delivery Order SPE2DB24D1205-SPE2DB25FCZEM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,396.26 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations. This firm fixed-price, non-set-aside delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml formulation) with a ceiling value of $19,962.14. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a typical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $9,392.34 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitively awarded, firm fixed-price contract was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the open...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) pre-filled pens with a ceiling value of $3,519.05. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at $11,020.09 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml) with an ultimate completion date of July 28, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ozempic (insulin glargine) 0.25-0.5 mg/dose pens in 3 mL vials, with a ceiling value of $15,992.27. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract is due for completion by July 30, 2025, and represents a single delivery transaction under...
- The Defense Logistics Agency (DLA) awarded a $10,739.93 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL). This firm fixed-price delivery order is scheduled for completion by July 24, 2025, and will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal procurement requirements through...
- The Defense Logistics Agency awarded a delivery order valued at $5,292.97 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml configurations. This competitively awarded, firm fixed-price contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a child order under a larger contract vehicle. The award is categorized as a delivery order rather than a standalone contract, indicating it was placed against...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZEMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml vials, with a ceiling value of $2,819.97. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and no set-aside designation was applied. The order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company maintains an extensive portfolio of competitively awarded federal contracts through the DLA Medical Supply Chain, covering a wide spectrum of pharmaceutical products including diabetes medications, neurological treatments, pain management drugs, antibiotics, and specialized medical supplies. The company's capability to fulfill this order reflects its established role as a primary pharmaceutical provider for Defense Health Agency and other government healthcare systems through flexible contract vehicles designed to support military medical operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/4/25 |